KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
63 hedge funds and large institutions have $204M invested in KalVista Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 23 increasing their positions, 20 reducing their positions, and 14 closing their positions.
15% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 20
5% more capital invested
Capital invested by funds: $194M → $204M (+$10.2M)
0.9% more ownership
Funds ownership: 89.56% → 90.46% (+0.9%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
13% less funds holding
Funds holding: 72 → 63 (-9)
64% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$7.01M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.53M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
+$1.51M |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$774K |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$349K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$3.29M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$1.16M |
| 3 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$1.05M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$900K |
| 5 |
Renaissance Technologies
New York
|
-$500K |
KALV Hedge Fund Activity: Q3 2020 in Review
63 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q3 2020, worth a combined $204M — up 5.3% from $194M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of KALV and 5 opened new positions — a net loss of 9 holders — while 20 trimmed existing stakes and 23 added.
The largest buyer was Wellington Management Group, adding an estimated $7.01M. The largest seller was Logos Global Management, cutting an estimated $3.29M.
- 63 institutional investors held KalVista Pharmaceuticals (KALV) as of Q3 2020, down from 72 in Q2 2020.
- Funds reported $204M of KalVista Pharmaceuticals stock for Q3 2020, up 5.3% quarter-over-quarter.
- 5 funds opened new KalVista Pharmaceuticals positions in Q3 2020 and 14 closed out, a net change of -9 holders.
- The largest KalVista Pharmaceuticals buyer in Q3 2020 was Wellington Management Group, an estimated $7.01M added.
- The largest KalVista Pharmaceuticals seller in Q3 2020 was Logos Global Management, an estimated $3.29M sold.
Based on aggregated 13F filings for Q3 2020.